Unity Biotechnology, Inc. (UBX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
UBX currently has 16.9M outstanding shares. with significant dilution risk as 106M authorized shares could dilute existing holders by 627.1%. The company has minimally diluted shareholders by 0.46% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Sep 25, 2025 |
POS AM filing: This is a post-effective amendment to deregister all unsold securities from previous registration statements due to the company's plan of dissolution. |
17M | 110M |
| Sep 25, 2025 |
POS AM filing: This post-effective amendment removes from registration all securities of the Company registered under the Registration Statements on Form S-3 that remain unsold. |
17M | 110M |
| Apr 22, 2025 |
10-Q filing | 16.9M shares outstanding |
17M | 730M |
| Mar 07, 2025 |
10-K filing | 16.8M shares outstanding |
17M | 730M |
| Nov 04, 2024 |
10-Q filing | 16.8M shares outstanding |
17M | 730M |
| Aug 06, 2024 |
10-Q filing | 16.8M shares outstanding |
17M | 730M |
| May 14, 2024 |
10-Q filing | 16.8M shares outstanding |
17M | 730M |
| Apr 15, 2024 |
10-K filing | 16.8M shares outstanding |
17M | 730M |
| Dec 06, 2023 |
S-3 filing: This prospectus relates to the resale by the selling stockholders of up to 2,271,580 shares of common stock, including shares issuable upon exercise of warrants. |
14M | 730M |
| Nov 13, 2023 |
10-Q filing | 14.6M shares outstanding |
15M | 730M |
| Nov 13, 2023 |
8-K filing: UNITY Biotechnology, Inc. entered into an inducement offer letter agreement with certain warrant holders to exercise their existing warrants for cash at a reduced price, and the Company will issue new warrants. ($4.38M proceeds) |
14M | 730M |
| Aug 08, 2023 |
10-Q filing | 14.4M shares outstanding |
14M | 730M |
| May 09, 2023 |
10-Q filing | 14.3M shares outstanding |
14M | 730M |
| Mar 15, 2023 |
10-K filing | 14.3M shares outstanding |
14M | 730M |
| Nov 08, 2022 |
10-Q filing | 14.2M shares outstanding |
14M | 730M |
| Oct 14, 2022 |
S-3 filing: Unity Biotechnology, Inc. files an S-3 to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
140M | 600M |
| Aug 12, 2022 |
10-Q filing | 69.2M shares outstanding |
69M | 53M |
| May 10, 2022 |
10-Q filing | 69.2M shares outstanding |
69M | 53M |
| Mar 15, 2022 |
10-K filing | 68.9M shares outstanding |
69M | 54M |
| Mar 15, 2022 |
S-3 filing: Unity Biotechnology, Inc. may offer and sell up to $125,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
63M | 60M |
| Nov 10, 2021 |
10-Q filing | 57.7M shares outstanding |
58M | 0 |
| Aug 10, 2021 |
10-Q filing | 55.1M shares outstanding |
55M | 0 |
| May 11, 2021 |
10-Q filing | 54.9M shares outstanding |
55M | 0 |
| Mar 23, 2021 |
10-K filing | 54.7M shares outstanding |
55M | 0 |
| Nov 04, 2020 |
10-Q filing | 52.9M shares outstanding |
53M | 0 |
| Jul 31, 2020 |
10-Q filing | 52.0M shares outstanding |
52M | 0 |
| May 07, 2020 |
10-Q filing | 49.1M shares outstanding |
49M | 0 |
| Mar 11, 2020 |
10-K filing | 47.6M shares outstanding |
48M | 0 |